|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PARPBP |
Gene summary for PARPBP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PARPBP | Gene ID | 55010 |
| Gene name | PARP1 binding protein | |
| Gene Alias | AROM | |
| Cytomap | 12q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | B4DZ31 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55010 | PARPBP | HCC1_Meng | Human | Liver | HCC | 4.58e-11 | 4.44e-02 | 0.0246 |
| 55010 | PARPBP | HCC1 | Human | Liver | HCC | 8.27e-05 | 3.12e+00 | 0.5336 |
| 55010 | PARPBP | HCC2 | Human | Liver | HCC | 2.78e-04 | 1.18e+00 | 0.5341 |
| 55010 | PARPBP | S014 | Human | Liver | HCC | 1.68e-10 | 3.22e-01 | 0.2254 |
| 55010 | PARPBP | S015 | Human | Liver | HCC | 6.11e-04 | 2.13e-01 | 0.2375 |
| 55010 | PARPBP | S016 | Human | Liver | HCC | 3.39e-08 | 2.64e-01 | 0.2243 |
| 55010 | PARPBP | S028 | Human | Liver | HCC | 1.47e-06 | 3.79e-01 | 0.2503 |
| 55010 | PARPBP | S029 | Human | Liver | HCC | 6.39e-07 | 2.84e-01 | 0.2581 |
| 55010 | PARPBP | C04 | Human | Oral cavity | OSCC | 1.87e-04 | 2.99e-01 | 0.2633 |
| 55010 | PARPBP | C21 | Human | Oral cavity | OSCC | 4.28e-08 | 3.37e-01 | 0.2678 |
| 55010 | PARPBP | C30 | Human | Oral cavity | OSCC | 7.35e-08 | 5.05e-01 | 0.3055 |
| 55010 | PARPBP | C38 | Human | Oral cavity | OSCC | 1.16e-07 | 5.57e-01 | 0.172 |
| 55010 | PARPBP | C43 | Human | Oral cavity | OSCC | 8.66e-11 | 2.17e-01 | 0.1704 |
| 55010 | PARPBP | C46 | Human | Oral cavity | OSCC | 8.53e-08 | 2.04e-01 | 0.1673 |
| 55010 | PARPBP | C51 | Human | Oral cavity | OSCC | 3.99e-03 | 2.45e-01 | 0.2674 |
| 55010 | PARPBP | C08 | Human | Oral cavity | OSCC | 9.07e-06 | 1.56e-01 | 0.1919 |
| 55010 | PARPBP | LN46 | Human | Oral cavity | OSCC | 3.49e-07 | 2.97e-01 | 0.1666 |
| 55010 | PARPBP | SYSMH2 | Human | Oral cavity | OSCC | 9.07e-06 | 2.37e-01 | 0.2326 |
| 55010 | PARPBP | SYSMH3 | Human | Oral cavity | OSCC | 8.75e-05 | 1.61e-01 | 0.2442 |
| 55010 | PARPBP | P4_cSCC | Human | Skin | cSCC | 2.54e-06 | 2.58e-01 | -0.00290000000000005 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
| GO:2001020110 | Esophagus | ESCC | regulation of response to DNA damage stimulus | 145/8552 | 219/18723 | 5.97e-10 | 1.50e-08 | 145 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:00062826 | Esophagus | ESCC | regulation of DNA repair | 82/8552 | 130/18723 | 4.65e-05 | 3.66e-04 | 82 |
| GO:200102112 | Esophagus | ESCC | negative regulation of response to DNA damage stimulus | 54/8552 | 81/18723 | 1.09e-04 | 7.64e-04 | 54 |
| GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
| GO:20007793 | Esophagus | ESCC | regulation of double-strand break repair | 52/8552 | 85/18723 | 2.86e-03 | 1.21e-02 | 52 |
| GO:00007241 | Esophagus | ESCC | double-strand break repair via homologous recombination | 79/8552 | 138/18723 | 4.05e-03 | 1.62e-02 | 79 |
| GO:00007251 | Esophagus | ESCC | recombinational repair | 80/8552 | 140/18723 | 4.10e-03 | 1.63e-02 | 80 |
| GO:005105221 | Liver | HCC | regulation of DNA metabolic process | 198/7958 | 359/18723 | 7.62e-07 | 1.17e-05 | 198 |
| GO:200102021 | Liver | HCC | regulation of response to DNA damage stimulus | 128/7958 | 219/18723 | 1.31e-06 | 1.90e-05 | 128 |
| GO:00062824 | Liver | HCC | regulation of DNA repair | 74/7958 | 130/18723 | 6.27e-04 | 3.89e-03 | 74 |
| GO:00063021 | Liver | HCC | double-strand break repair | 131/7958 | 251/18723 | 1.17e-03 | 6.54e-03 | 131 |
| GO:2000779 | Liver | HCC | regulation of double-strand break repair | 47/7958 | 85/18723 | 1.17e-02 | 4.28e-02 | 47 |
| GO:005105210 | Oral cavity | OSCC | regulation of DNA metabolic process | 207/7305 | 359/18723 | 4.45e-13 | 2.17e-11 | 207 |
| GO:200102017 | Oral cavity | OSCC | regulation of response to DNA damage stimulus | 131/7305 | 219/18723 | 3.21e-10 | 8.72e-09 | 131 |
| GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
| GO:00062825 | Oral cavity | OSCC | regulation of DNA repair | 75/7305 | 130/18723 | 1.19e-05 | 1.21e-04 | 75 |
| GO:20010213 | Oral cavity | OSCC | negative regulation of response to DNA damage stimulus | 49/7305 | 81/18723 | 7.27e-05 | 5.72e-04 | 49 |
| GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PARPBP | SNV | Missense_Mutation | c.1348G>C | p.Ala450Pro | p.A450P | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0T3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| PARPBP | SNV | Missense_Mutation | c.1879A>G | p.Lys627Glu | p.K627E | protein_coding | deleterious(0.04) | benign(0.037) | TCGA-AC-A2FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR | ||
| PARPBP | SNV | Missense_Mutation | c.1076C>T | p.Ser359Leu | p.S359L | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PARPBP | SNV | Missense_Mutation | novel | c.1216N>C | p.Thr406Pro | p.T406P | protein_coding | deleterious(0.03) | benign(0.013) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PARPBP | SNV | Missense_Mutation | novel | c.29N>T | p.Ser10Leu | p.S10L | protein_coding | tolerated(1) | benign(0) | TCGA-EA-A4BA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| PARPBP | SNV | Missense_Mutation | rs758656040 | c.994A>G | p.Asn332Asp | p.N332D | protein_coding | tolerated(0.5) | benign(0.011) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PARPBP | SNV | Missense_Mutation | rs143436739 | c.1727N>T | p.Ser576Leu | p.S576L | protein_coding | tolerated(0.34) | benign(0.006) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PARPBP | insertion | Frame_Shift_Ins | novel | c.891_892insT | p.Leu299PhefsTer8 | p.L299Ffs*8 | protein_coding | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |||
| PARPBP | insertion | Frame_Shift_Ins | novel | c.876_877insA | p.Gln294ThrfsTer13 | p.Q294Tfs*13 | protein_coding | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |||
| PARPBP | SNV | Missense_Mutation | novel | c.1482N>T | p.Glu494Asp | p.E494D | protein_coding | tolerated(0.12) | possibly_damaging(0.655) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |